Shionogi & Co., Ltd. (TYO:4507)
Japan
· Delayed Price · Currency is JPY 2,638.50
-67.00 (-2.48%)
Aug 14, 2025, 3:30 PM JST
Shionogi & Revenue
Shionogi & had revenue of 99.78B JPY in the quarter ending June 30, 2025, with 2.25% growth. This brings the company's revenue in the last twelve months to 440.50B, up 4.05% year-over-year. In the fiscal year ending March 31, 2025, Shionogi & had annual revenue of 438.27B with 0.73% growth.
Revenue (ttm)
440.50B
Revenue Growth
+4.05%
P/S Ratio
5.23
Revenue / Employee
88.90M
Employees
4,955
Market Cap
2,301.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 438.27B | 3.19B | 0.73% |
| Mar 31, 2024 | 435.08B | 8.40B | 1.97% |
| Mar 31, 2023 | 426.68B | 91.55B | 27.32% |
| Mar 31, 2022 | 335.14B | 37.96B | 12.77% |
| Mar 31, 2021 | 297.18B | -36.19B | -10.86% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.22B |
| Takeda Pharmaceutical Company | 4,480.25B |
| HOYA Corporation | 876.09B |
| Daiichi Sankyo Company | 1,924.68B |
| Otsuka Holdings | 2,401.70B |
| Terumo | 1,037.94B |
| Astellas Pharma | 1,944.99B |
| Olympus | 969.02B |
Shionogi & News
- 16 days ago - Shionogi & Co., Ltd. 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 16 days ago - Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Shionogi & Co. reports Q1 results - Seeking Alpha
- 3 months ago - Shionogi & Co. GAAP EPS of ¥200.29, revenue of ¥438.27B - Seeking Alpha
- 3 months ago - Shionogi to buy Japan Tobacco’s Torii Pharma in a deal worth over $1B - Seeking Alpha
- 6 months ago - Shionogi and Jordan's Guardian Angels Announce First-Ever Human Drug Study for Jordan's Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder - Benzinga
- 6 months ago - Shionogi & Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 6 months ago - Shionogi targets JPY550B revenue through QOL focus and global expansion - Seeking Alpha